Last reviewed · How we verify
Minirin
Minirin is a Small molecule drug developed by Hormozgan University of Medical Sciences. It is currently FDA-approved for Hereditary factor VIII deficiency disease, Nocturnal enuresis, Partial Central Diabetes Insipidus. Also known as: Desmopressin acetate.
At a glance
| Generic name | Minirin |
|---|---|
| Also known as | Desmopressin acetate |
| Sponsor | Hormozgan University of Medical Sciences |
| Target | Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Hereditary factor VIII deficiency disease
- Nocturnal enuresis
- Partial Central Diabetes Insipidus
- Polyuria
- von Willebrand disorder
Common side effects
Key clinical trials
- DDAVP for Pituitary Adenoma (NA)
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
- Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency (NA)
- Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis (NA)
- NOCDURNA PASS Study Using Registries in Denmark, Germany and Sweden
- Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome (PHASE2)
- Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE (PHASE3)
- DDAVP Effect by TEG6 in Cardiac Surgery
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Minirin CI brief — competitive landscape report
- Minirin updates RSS · CI watch RSS
- Hormozgan University of Medical Sciences portfolio CI
Frequently asked questions about Minirin
What is Minirin?
Minirin is a Small molecule drug developed by Hormozgan University of Medical Sciences, indicated for Hereditary factor VIII deficiency disease, Nocturnal enuresis, Partial Central Diabetes Insipidus.
What is Minirin used for?
Minirin is indicated for Hereditary factor VIII deficiency disease, Nocturnal enuresis, Partial Central Diabetes Insipidus, Polyuria, von Willebrand disorder.
Who makes Minirin?
Minirin is developed and marketed by Hormozgan University of Medical Sciences (see full Hormozgan University of Medical Sciences pipeline at /company/hormozgan-university-of-medical-sciences).
Is Minirin also known as anything else?
Minirin is also known as Desmopressin acetate.
What development phase is Minirin in?
Minirin is FDA-approved (marketed).
What does Minirin target?
Minirin targets Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor.
Related
- Target: All drugs targeting Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor
- Manufacturer: Hormozgan University of Medical Sciences — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Hereditary factor VIII deficiency disease
- Indication: Drugs for Nocturnal enuresis
- Indication: Drugs for Partial Central Diabetes Insipidus
- Also known as: Desmopressin acetate
- Compare: Minirin vs similar drugs
- Pricing: Minirin cost, discount & access